DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study
Authors:
- Luca BelloLBLuca Bello
- Eric P. HoffmanEHEric P. Hoffman
- Craig M. McDonaldCMCraig M. McDonald
- Sebahattin CirakSCSebahattin Cirak
- CINRG investigatorsCICINRG investigators
- A. CnaanACA. Cnaan
- M. ThangarajhMTM. Thangarajh
- R.T. AbreschRAR.T. Abresch
- E. HenricsonEHE. Henricson
- V. ViswanathanVVV. Viswanathan
- 26 July 2016
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 87 (4) , 401-409
Abstract
Objective: To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations in a large, prospective natural history study of Duchenne muscular dystrophy (DMD), with particular attention to mutations amenable to emerging molecular treatments. Methods: We analyzed data from the Cooperative International Neuromuscular Research Group Duchenne Natural History Study for participants with DMD single- or multi-exon deletions or duplications with defined exon boundaries (n = 186), or small mutations identified by sequencing (n = 26, including 16 nonsense point mutations). We performed a time-to-event analysis of LoA, a strong indicator of overall disease severity, adjusting for glucocorticoid treatment and genetic modifiers. Results: Participants with deletions amenable to skipping of exon 44 had later LoA (median 14.8 years, hazard ratio 0.31, 95% confidence interval 0.14–0.69, p = 0.004). Age at LoA did not differ significantly in participants with deletions amenable to exon 45, 51, and 53 skipping, duplications, and small rearrangements. Nonsense mutation DMD also showed a typical median age at LoA (11.1 years), with a few outliers (ambulatory around or after 16 years of age) carrying stop codons within in-frame exons, more often situated in the rod domain. Conclusions: As exon 44 skipping–amenable DMD has a later LoA, mutation-specific randomization and selection of placebo groups are essential for the success of clinical trials.Keywords
This publication has 40 references indexed in Scilit:
- 24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular DystrophyPLOS ONE, 2013
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyThe Lancet, 2011
- Systemic Administration of PRO051 in Duchenne's Muscular DystrophyNew England Journal of Medicine, 2011
- SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophyNeurology, 2011
- Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD geneHuman Mutation, 2010
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept studyThe Lancet Neurology, 2009
- Local Dystrophin Restoration with Antisense Oligonucleotide PRO051New England Journal of Medicine, 2007
- Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame ruleMuscle & Nerve, 2006
- Intronic breakpoint definition and transcription analysis in DMD/BMD patients with deletion/duplication at the 5′ mutation hot spot of the dystrophin geneGene, 2006
- Deletions in the 5' region of dystrophin and resulting phenotypes.Journal of Medical Genetics, 1994